The form is not published.

Heading

Tafasitamab Treatment Option Approved for Relapsed or Refractory Follicular Lymphoma in US

Tafasitamab Treatment Option Approved for Relapsed or Refractory Follicular Lymphoma in US

In June 2025, the U.S. Food and Drug Administration (FDA) approved a new combination treatment option for adults with relapsed ...
/
womans face

Angela’s story

My name is Angela. I live in New York State in the US with my husband of 37 years, who ...
/
Upcoming Webinar: FLF Post-ICML Webinar - Charting Our Progress towards a Cure

Upcoming Webinar: FLF Post-ICML Webinar – Charting Our Progress towards a Cure

Join us for an informative webinar where we discuss some of the key topics covered during our Satellite Symposium held ...
/
Top 10 tips to help you open up conversations about cancer

Top 10 tips to help you open up conversations about cancer

[et_pb_section][et_pb_row][et_pb_column type="4_4"][et_pb_text]Home » News » Blog Cancer conversations are not only challenging but can also be emotionally daunting, especially when ...
/
The power of positivity: Embracing optimism with follicular lymphoma

The power of positivity: Embracing optimism with follicular lymphoma

[et_pb_section][et_pb_row][et_pb_column type="4_4"][et_pb_text]Home » News » Blog Receiving a diagnosis of follicular lymphoma can feel like an emotional earthquake, and it's ...
/
The Power of Seed Funding: Accelerating Research in Follicular Lymphoma

The Power of Seed Funding: Accelerating Research in Follicular Lymphoma

One example of the impactful ways we advance our mission to cure follicular lymphoma (FL) is through our seed funding ...
/